Fennec Pharmaceuticals INC 8-K filings

Fennec Pharmaceuticals shareholders approved all director nominees and corporate proposals at the 2026 annual meeting.

Fennec Pharmaceuticals has granted 50,000 stock options to three new employees under its 2026 Equity Inducement Plan.

Fennec Pharmaceuticals Inc. announced the upcoming retirement of a Board of Directors member and a reduction in the Board's size.

Fennec Pharmaceuticals announced that four abstracts evaluating its drug PEDMARK (sodium thiosulfate injection) have been accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting.

Fennec Pharmaceuticals announced the initiation of an investigator-sponsored study by the University of Arizona Cancer Center to evaluate PEDMARK's use in adult patients with head and neck and testicular cancers receiving cisplatin.

Fennec Pharmaceuticals announced record full-year 2025 net PEDMARK product sales of $44.6 million, a 50% year-over-year increase, alongside strategic business advancements and a strengthened financial position.

Fennec Pharmaceuticals Inc. has settled its patent litigation with Cipla, securing market exclusivity for its PEDMARK product until at least September 1, 2033.

Fennec Pharmaceuticals announced a new real-world study of PEDMARK for cisplatin-induced hearing loss in adolescent and adult cancer patients.

Fennec Pharmaceuticals announced an investigator-sponsored clinical study to evaluate PEDMARK for preventing cisplatin-induced hearing loss in adult men with metastatic testicular germ cell tumors.

Fennec Pharmaceuticals announced positive topline results from a Phase 2/3 clinical trial in Japan for PEDMARK, significantly reducing cisplatin-induced hearing loss in pediatric cancer patients.

Fennec Pharmaceuticals Inc. announced the full repurchase and redemption of all its outstanding convertible notes, eliminating all company debt.

Fennec Pharmaceuticals Inc. closed a private offering of common shares, raising $5.025 million to partially repurchase convertible notes and for general corporate purposes.

Fennec Pharmaceuticals Inc. announced the pricing of an underwritten public offering of 4,666,667 common shares at $7.50 per share, aiming to raise approximately $35 million gross proceeds.

Fennec Pharmaceuticals Inc. announced that its shareholders approved all proposals, including the election of six directors, the appointment of its independent public accounting firm, and advisory votes on executive compensation and the 2020 Equity Incentive Plan amendment, at its annual meeting held on June 3, 2025.

Fennec Pharmaceuticals announces a 40% year-over-year increase in PEDMARK net product sales, reaching $29.6 million for the full year 2024, and provides a business update.

Fennec Pharmaceuticals' partner, Norgine Pharmaceuticals, has launched PEDMARQSI in Germany, marking a significant step in the global commercialization of the drug for preventing cisplatin-induced ototoxicity.

Fennec Pharmaceuticals announced that its partner, Norgine Pharmaceuticals, received positive draft guidance from NICE recommending PEDMARQSI for preventing cisplatin-induced hearing loss in young patients.

Fennec Pharmaceuticals has announced the early repayment of $13 million of its convertible debt, leading to reduced interest expenses and potential share dilution.

Fennec Pharmaceuticals has appointed a new Chief Medical Officer, Chief Commercial Officer, and Chief Strategy Officer to drive the company's next phase of growth.

Fennec Pharmaceuticals has appointed Jeffrey S. Hackman as its new CEO, succeeding Rostislav Raykov, who will remain on the board of directors.

Fennec Pharmaceuticals' Chief Operating Officer, Adrian Haigh, has departed from his role effective June 30, 2024, following a transition from his position as an independent director.

Fennec Pharmaceuticals Inc. held its annual shareholder meeting on June 25, 2024, where all proposals, including the election of directors and the appointment of an auditor, were approved.

Fennec Pharmaceuticals will release its first quarter 2024 financial results before the US market opens on May 14, 2024, followed by a conference call and webcast to discuss the results.

Fennec Pharmaceuticals announced full-year 2023 financial results, highlighted by $21.3 million in PEDMARK net product sales and a significant licensing agreement for PEDMARQSI.

Fennec Pharmaceuticals has granted Norgine exclusive rights to commercialize PEDMARQSI in key international markets, securing a substantial upfront payment and potential future milestones.

Fennec Pharmaceuticals reported preliminary unaudited net revenues for the fourth quarter of 2023 between $9.2 and $9.7 million, and full-year 2023 net revenues between $20.7 and $21.2 million.

Fennec Pharmaceuticals reports preliminary unaudited Q4 2023 net revenues of $9.2 to $9.7 million, a significant increase over the previous quarter.

The FDA has publicly reminded healthcare providers that PEDMARK, a drug used to reduce hearing loss in pediatric cancer patients, should not be substituted with other sodium thiosulfate products due to potential health risks.